Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation

References

• Beletsi A, Panagi Z, Avgoustakis K. (2005). Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA–PEG diblock copolymers. Int J Pharm 298:233–41
   PubMed Web of Science ®Google Scholar
• Gref R, Domb A, Quellec P, et al. (1995). The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 16:215–32
   PubMed Web of Science ®Google Scholar
• Harris JM, Martin NE, Modi M. (2001). Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539–51
   PubMed Web of Science ®Google Scholar
• Jia L, Shen J, Zhang D, et al. (2012). In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. Int J Biol Macromol 50:523–9
   PubMed Web of Science ®Google Scholar
• Jia L, Zhang D, Li Z, et al. (2010). Nanostructured lipid carriers for parenteral delivery of silybin: biodistribution and pharmacokinetic studies. Colloids Surf B Biointerfaces 80:213–8
   PubMed Web of Science ®Google Scholar
• Joshi MD, Müller RH. (2009). Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 71:161–72
   PubMed Web of Science ®Google Scholar
• Kaur IP, Bhandari R, Bhandari S, Kakkar V. (2008). Potential of solid lipid nanoparticles in brain targeting. J Control Release 127:97–109
   PubMed Web of Science ®Google Scholar
• Kawahara K, Nishi K, Suenobu M, et al. (2009). Oral administration of synthetic retinoid Am80 (Tamibarotene) decreases brain β-amyloid peptides in APP23 Mice. Biol Pharm Bull 32:1307–9
   PubMed Web of Science ®Google Scholar
• Kim HK, Davaa E, Myung CS, Park JS. (2010). Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Int J Pharm 392:141–7
   PubMed Web of Science ®Google Scholar
• Kimura Y, Oyashiki K. (2005). Evaluation of the new drug by the clinician. Tamibarotene. Clin Pract 24:991–3
   Google Scholar
• Lipka J, Semmler-Behnke M, Sperling RA, et al. (2010). Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 31:6574–81
   PubMed Web of Science ®Google Scholar
• Liu D, Liu Z, Wang L, et al. (2011). Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 85:262–9
   PubMed Web of Science ®Google Scholar
• Liu D, Wang L, Liu Z, et al. (2010). Preparation, characterization, and in vitro evaluation of docetaxel-loaded poly (lactic acid)-poly (ethyleneglycol) nanoparticles for parenteral drug delivery. J Biomed Nanotechnol 6:675–82
   PubMed Web of Science ®Google Scholar
• Liu X, Wang Z, Feng R, et al. (2013). A novel approach for systematic delivery of a hydrophobic anti-leukemia agent Tamibarotene mediated by nanostructured lipid carrier. J Biomed Nanotechnol 9:1586–93
   PubMed Web of Science ®Google Scholar
• Luo Q, Zhao J, Zhang X, Pan W. (2011). Nanostructured lipid carrier (NLC) coated with Chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 403:185–91
   PubMed Web of Science ®Google Scholar
• Malugin A, Ghandehari H. (2010). Cellular uptake and toxicity of gold nanoparticles in prostate cancer cells: a comparative study of rods and spheres. J Appl Toxicol 30:212–7
   PubMed Web of Science ®Google Scholar
• Miwako I, Kagechika H. (2007). Tamibarotene. Drugs Today (Barc) 43:563–8
   PubMed Web of Science ®Google Scholar
• Ohnishi K. (2007). PML-RARa inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. Int J Clin Oncol 12:313–7
   PubMed Web of Science ®Google Scholar
• Oikawa T, Okayasu I, Ashino H, et al. (1993). Three novel synthetic retinoids, Re 80, Am 580 and Am 80, all exhibit anti-angiogenic activity in vivo. Eur J Pharmacol 249:113–6
   PubMed Web of Science ®Google Scholar
• Shen J, Wang Y, Ping Q, et al. (2009). Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Release 137:217–23
   PubMed Web of Science ®Google Scholar
• Shudo K, Kagechika H, Yamazaki N, et al. (2004). A synthetic retinoid Am80 (Tamibarotene) rescues the memory deficit caused by scopolamine in a passive avoidance paradigm. Biol Pharm Bull 27:1887–9
   PubMed Web of Science ®Google Scholar
• Stolnik S, Illum L, Davis SS. (1995). Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 16:195–214
   Web of Science ®Google Scholar
• Storm G, Belliot SO, Daemen T, Lasic DD. (1995). Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 17:31–48
   Web of Science ®Google Scholar
• Sugitani M, Abe R, Ikarashi N, et al. (2009). Disposition of a new tamibarotene prodrug in mice. Biol Pharm Bull 32:1997–2001
   PubMed Web of Science ®Google Scholar
• Su Z, Niu J, Xiao Y, et al. (2011). Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine. Mol Pharm 8:1641–51
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Yano T, Omoto E, et al. (1997). Re-induction of complete remission with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukaemia previously treated with all-trans retinoic acid. Br J Haematol 97:137–40
   PubMed Web of Science ®Google Scholar
• Tobita T, Takeshita A, Kitamura K, et al. (1997). Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 90:967–73
   PubMed Web of Science ®Google Scholar
• Xu X, Zhao C, Yang H, et al. (2011). Anti-inflammatory activity of injectable dexamethasone acetate-loaded nanostructured lipid carriers. Drug Deliv 18:485–92
   PubMed Web of Science ®Google Scholar
• Yang X, Li Y, Li M, et al. (2012). Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 334:338–45
   PubMed Web of Science ®Google Scholar
• Yuan H, Wang L, Du Y, et al. (2007). Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf B Biointerfaces 60:174–9
   PubMed Web of Science ®Google Scholar
• Zhang T, Chen J, Zhang Y, et al. (2011). Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 43:174–9
   PubMed Web of Science ®Google Scholar
• Zhang X, Pan W, Gan L, et al. (2008). Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem Pharm Bull 56: 1645–50
   PubMed Web of Science ®Google Scholar